ORIGINAL PAPER

Can re-TURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience

Roberto Giulanelli 1, Barbara Cristina Gentile 1, Gabriella Mirabile 1, Luca Albanesi 1, Paola Tariciotti 1, Giorgio Rizzo 1, Maurizio Buscarini 2, Mauro Vermiglio 3

1 CUrA, Nuova Villa Claudia Clinic, Rome, Italy;
2 Campus Biomedico, Rome, Italy;
3 Villa Giosa Clinic, Sora (FR), Italy.

Summary
Introduction: Understaging after initial transurethral resection is common in patients with high-risk non muscle infiltrating bladder cancer (NMIBC) and can delay accurate diagnosis and definitive treatment. The rate of upstaging from T1 to T2 disease after repeated transurethral resection ranges from 0 to 28%, although the rate of upstaging may be even higher up to 49% when muscularis propria is absent in the first specimen. A restaging classic transurethral resection of bladder tumour (re-TURBT) is the better predictor of early stage progression. According to some reports, the rate of positivity for tumor in re-TURBT performed within eight weeks after initial TURBT was as high as 18-77%, and in about 40% of the patients a change in tumor stage was reported. We aimed to investigate, in high risk group, the presence of residual tumor following white light classical transurethral resection of bladder tumor (WLre-TURBT) and the different recurrence and progression rate between patients with persistent or negative (pT0) oncological disease after WLre-TURBT.

Materials and methods: A cohort of 285 patients presenting with primitive bladder cancer underwent to WLcTURBT from January 2011 to December 2015; out of them 92 (32.28%) were T1HG. In according to EAU guidelines 2011, after 4-6 weeks all HG bladder cancer patients underwent a WL re-TURBT. All patients were submitted to a subsequent follow-up including cystoscopy every 3 months with multiple biopsies, randomly and in the previous zone of resection; urinary cytology on 3 specimens and kidney/bladder ultrasound every 6 months. The average follow-up was 48 months.

Results: Following WLre-TURBT we observed a persistent disease in 18 (15.2%) patients: 14 (77.7%) with a HG-NMIBC and 4 (22.2%) with a high grade (HG) muscle invasive bladder cancer (pT2HG). After follow-up of all 92 patients according to the guidelines EAU, we observed recurrence in 36/92 (39.1%) and progression in 14/92 (15.2%). Of 14 NMIBC with persistent disease, 10 patients (71.4%) showed recurrence: 4 patients (40%) were pT1HG with concomitant carcinoma in situ (CIS), 3 patients (30%) multifocal pTahG, 2 (20%) patients CIS and one patient (10%) a muscle invasive neoplasm (pT2HG).

Instead of the group of 48 patients pT1 following WL re-TURBT, we observed recurrence in 26 patients (54.1%) and in two patients (4.1%) progressions, who presented after 3 months in association with CIS. The remaining 22 patients (45.9%) with initial pT1HG are still progression free. Multivariate analysis showed that the most important variable of early recurrence were persistent neoplasm and histopathological findings at WLre-TURBT (p = 0.01), followed by the result of the first cystoscopy (p = 0.002) and presence of CIS (p = 0.02).

Discussion: Following WLre-TURBT in HG-NMIBC patients we identified in 13% of cases a persistent disease with a 4.3% of MIBC. In the high risk persistent bladder neoplasms group we observed recurrent and progression rate higher than in T0 bladder tumours group ( p = 0.05).

Key words: pT1HG; WLre-cTURBT; BCG schedule; pCISHG Recurrence and progression rate.

Submitted 14 November 2016; Accepted 11 January 2017

Introduction
Bladder cancer is a common genitourinary malignancy, with transitional cell carcinoma comprising nearly 90% of all primary bladder tumours. At the first diagnosis 70% to 80% of urothelial tumours are confined to the epithelium, the remainder is characterized by muscle invasion. A significant number of patients with high risk non-muscle invasive bladder tumours (HG-NMIBT) treated with white light classic transurethral resection of bladder tumours (WLcTURBT) and intravesical BCG will progress to invasive disease (1-3). Progression to muscle invasion (pT2) mandates immediate radical cystectomy (4).

WLcTURBT is the standard initial therapy for NMIBT, but the high percentage of recurrence after surgery is still an unresolved problem (5). High grade pT1 bladder neoplasm (pT1HG) really represents a therapeutic challenge due to the high risk of progression (about 15-30%) to muscle-invasive disease, usually within 5 years (6).

However, no consensus exists regarding the treatment of patients with recurrent bladder tumours that invade the lamina propria (pT1) (7-9). Recent studies suggested that the first cTURBT may be incomplete in a significant number of cases (10). Understaging at the time of the initial transurethral resection is common for patients with high-risk NMIBT and can delay accurate diagnosis and definitive treatment. It is therefore recommended for patients with high-risk disease and in those with large or multiple tumors or when the initial transurethral resection is incomplete, to repeat WLre-cTURBT within 2-6
weeks in order to guide appropriate management (11). We aimed to investigate, in high risk group, the presence of residual tumor following WLC-TURBT and the different recurrence and progression rate between patients with persistent or negative (pT0) oncological disease after WLre-cTURBT.

**Materials and Methods**

In our department from January 2011 to June 2015, 285 consecutive patients with a first diagnosis of clinical bladder tumor underwent WLcTURBT. Histopathological findings showed 95 high grade (HG) bladder tumours invading the lamina propria (pT1) but only 92 (32.28%) cases were eligible for our study. Patients mean age was 68 years (range 42 to 78 yrs, SD 10.4); 22 patients were women; mean follow-up 28 months (range 16-5 months). Focality and dimensions are reported Table 1. We performed WLcTURBT with complete resection of all visible lesions and tumor bed and margins were taken separately. All resections were performed in our institution by the same experienced surgeon, R.G.

Our exclusion criteria included patients that underwent an incomplete resection or cases whose specimens were without muscle tissue in order to evaluate tumour invasion. We excluded three patients: two because of the lack of muscle tissue in the specimen and one because of the incomplete resection. A WLre-cTURBT, according to EAU guidelines (11), was routinely performed within 4 to 6 weeks following the first resection if the histopathological findings revealed T1 tumour. The surgeon performed the procedure with the same technique of the initial WLcTURBT: complete resection of all suspect residual tumour, separate resection of the underlying bladder wall with an adequate amount of detrusor muscle, wide resection of the margins to exclude the presence of carcinoma in situ (CIS) and associated biopsies with a loop resection (selected biopsies) of the abnormal areas of urothelium. If there was not residual tumour or if it was superficial, intravesical immunotherapy conforming to Lammi’s schedule was planned (12). In accordance to EAU guidelines (11), urine cytology and follow-up cystoscopy were performed every 3-month for the first year, biannually for the second year and annually thereafter. Ultrasonography of the urinary upper tract was performed every six months. However, if muscle invasive residual tumour or CIS were detected, subsequent treatment strategy was radical cystoprostatectomy.

Recurrence Free Survival, Progression Free Survival and Overall Survival curves were calculated by the Kaplan-Meier method (13) and compared by the log rank test (14). Statistical analysis was performed using the Pearson chi-square test (15). Tumors were classified according to the TNM system of the UICC (16) and Grading according to WHO classification. Patients were fully informed and consented the procedure.

**Results**

Of the 95 enrolled patients, 92 were considered evaluable for the actual analysis. After WLre-cTURBT performed within 4 to 6 weeks following the first resection, we observed 18 (19.5%) patients with recurrence: 4 (4.34%) with muscle invasive bladder cancer (MIBC) and 14 (15.2%) with NMIBC (Table 2). Regarding focality, dimension and concomitant CIS, all patients with invasive neoplasms were multifocal (p < 0.01), > 3 cm (p < 0.01) or with concomitant CIS (p < 0.001) to the first WLcTURBT.

All MIBC patients underwent radical cystoprostatectomy with staging lymphadenectomy and the histopathological evaluation revealed one patient with no evidence of TCC in the cystectomy specimen (pT0) and three patients with muscle invasion (pT2b) but no evidence of positive lymphnodes (pN0).

We carried out the follow up of all 92 patients according to the EAU guidelines, and we found out recurrence in 36/92 (39.1%) and progression in 14/92 (15.2%). All the 14 patients (15.2%) with NMIBC underwent intravesical immunotherapy conforming to Lammi’s schedule (12) and 10 (71.4%) of them showed recurrences respectively after 4, 6, 7, 10 and 12 months (see Table 3). Of these 10 patients, 4 patients (40%) showed recurrences pT1HG with concomitant CIS, 3 patients (30.0%) multifocal pTaHG, two (20.0%) CIS and one (10.0%) a muscle invasive neoplasm (pT2HG). All these patients with high grade persistent disease following BCG-schedule were regarded as “patients progressing” and after pelvis-abdomen CT and scintigraphy, radical cystoprostatectomy with staging lymphadenectomy was suggested.

The histopathological evaluation revealed two patients (2.17%) with no evidence of TCC in the cystectomy specimen (pT0), six patients (6.52%) with muscle invasive tumor pT2a and two (2.17%) pT2b, with no evidence of positive lymphnodes (pN0). All of the patients are actually living and disease-free but one (1.08) with muscle invasive tumor (pT2aN0) who died for another cause without evidence of disease progression. In the group of patients with

**Table 1.**

<table>
<thead>
<tr>
<th>Focality</th>
<th>Pts</th>
<th>Dimensions</th>
<th>Pts</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unifocal</td>
<td>14</td>
<td>&lt; 1 cm</td>
<td>12</td>
</tr>
<tr>
<td>Multifocal</td>
<td>78</td>
<td>&gt; 1 cm</td>
<td>54</td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt; 3 cm</td>
<td>26</td>
</tr>
<tr>
<td></td>
<td>92</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Table 2.**

| Re-TURBT | Pts | pT1 | pT2 |
|********|-----|-----|-----|
| Recurrences | 18  | 14  | 4   |
| %          | 19.50% | 15.10% | 4.40% |

**Table 3.**

<table>
<thead>
<tr>
<th>BCG</th>
<th>pT1HG/CIS</th>
<th>pTaHG/CIS</th>
<th>pT2HG/CIS</th>
<th>pT1HG/CIS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pts</td>
<td>10</td>
<td>3</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>15.20%</td>
<td>10.87%</td>
<td>3.27%</td>
<td>3.27%</td>
</tr>
</tbody>
</table>
cTURBT is strongly recommended regardless of the presence of muscle in specimens because of the possibility of understating due to incomplete resection (17, 18). It provides more accurate pathological staging information, since persistent tumor in second cTURBT specimens can be detected in 33%-55% of patients (19, 20). In our experience we observed persistent bladder lesions after WLRe-cTURBT in 19.5% of patients. In addition, a WLRe-cTURBT promotes cancer control. In a randomized controlled study, re-cTURBT decreased the recurrence rate compared to a single cTURBT (21). In our experience, in the persistent group, recurrences and progressions were more elevated than in T0 group. Persistent disease after WLRe-cTURBT is a poor prognostic indicator of recurrence and progression.

Dafiu et al. (22) demonstrated that, if a WLRe-cTURBT is performed, the risk of upstaging is near 30%, but the risk of residual tumour is still significant. We already reported our experience concerning the need of WLRe-cTURBT in patients with primary pT1 TCC of the bladder. Residual tumour rate was 19.5% in 18 patients who underwent WLRe-cTURBT following primary diagnosis of T1 disease and overall recurrence was 39.1%. Residual neoplasms were detected only in multifocal tumor, concomitant CIS and > 3 cm at first pT1HG bladder tumours. Our opinion is that the main and most important rule is a complete resection of the NMIBC. This procedure is not only mandatory for an adequate staging but also useful to the completion of WLcTURBT for most of the non muscle invasion tumours. An inadequate and incomplete resection increases recurrence rate as Brausi et al. (10) already showed: in fact the curative effect of an excellent resection is especially showed in superficial disease. Grimm et al. (23) investigated the role of WLRe-cTURBT in an heterogeneous group of patients with superficial bladder cancer. They found that the estimated risk of recurrence after 1, 2 and 3 years was 18%, 29% and 32% respectively and recurrence was observed in 38% pts treated with re-TURBT. Divrik et al. (24) found the recurrence rate was 13.6%, 22.3% and 31.2% in the first, the second and the third year respectively and that overall recurrence was 25.6%. Klan et al. (25) reported a residual tumour rate of 50% in patients with pT1 HG tumours, Herr (26) reported a rate of 74% residual tumours in 58 patients with pT1 HG bladder cancer, while Mersdorf et al. (27) detected residual tumours in 58% (26 of 45 patients) pT1HG bladder cancer. WLRe-cTURBT certainly detected a significant percentage of residual tumours and, among them, CIS and muscle invasive disease rates were reported with a range of 6% to 24% in different studies (28, 29).

Kitamura and Kakehi (30) suggested that optimal management strategies should be based on pathological find-

**Figure 1.** Kaplan-Meier overall recurrence survival analysis.

**Figure 2.** Kaplan-Meier overall progression survival analysis.

persistent disease following WLRe:TURBT we observed a overall MIBC rate of 66.6% (12 pts). Instead of the group of 48 patients who were T0 following WLre-cTURBT and had intravesical immunotherapy (BCG) conforming to Lammi’s schedule (12), we observed recurrence in 26 pts (54.1%) and in only two patients (4.1%) progression, who presented after 3 months, associated with CIS. The remaining 22 patients (45.9%) with initial T1HG are still progression free. Figures 1 and 2 show Kaplan-Meier overall recurrence-free and progression-free curves, respectively.

**Discussion**

WLcTURBT is the main-stay approach in the diagnosis and treatment of bladder cancer. On the basis of the EORTC risk tables and prognostic factors for T1HG bladder tumours, the probability of recurrence at 1 and 5 year, respectively, is 24-61% and 46-78%, and the probability of progression, respectively, is 1-17% and 6-45% (3). If patients are diagnosed with high-grade T1, a re-

Archivio Italiano di Urologia e Andrologia 2017; 89, 4
ings from second cTURBT specimens in patients with T1 disease. They recommended that patients with T0 upon WLRc-TURBT should be considered for BCG therapy or watchful waiting. A randomized controlled study is ongoing comparing watchful waiting to BCG therapy in high-grade T1 disease with T0 on WLRc-TURBT.

BCG instillation into bladder is the gold standard for conservative treatment for high-grade T1 disease. The therapeutic effect of BCG in high-grade T1 has already been established by several meta-analysis studies (31, 32). However, we have to keep in mind that patients die upon progression to MIBC, not upon recurrence, and that the effectiveness of BCG at preventing progression was not as great as its effectiveness at preventing recurrence. Further, residual tumor in the WLRc-TURBT specimen is associated with poor prognosis. In our experience, we observed progressions in 14/92 patients (15.2%): 12 from the group with persistent disease group and two in T0 patients. In the persistent disease group, we identified four patients with muscle invasive disease at WLRc-TURBT and 8 more patients during the follow-up. According to EAU guidelines (11), all patients were submitted to radical cystectomy and staging lymphadenectomy. All patients who had a muscle-invasive disease, confined within the muscle layer, without extra-partial extension or lymphadenopathy, are today living (NED). Early cystectomy was mandatory to have good results.

Cystectomy has definite advantages for high-grade T1 disease. In the largest study so far, the clinical outcomes of 167 patients with high-grade T1 were reviewed after cystectomy (33). Surprisingly, almost 30% experienced disease recurrence, and 18.5% died from bladder cancer. The cases had disease upstaging, and 27.5% had extravesical disease. A greater than 3-month delay between cystectomy and last WLRc-TURBT showed a trend toward upstaging, which means that delaying cystectomy for BCG therapy may worsen prognosis.

Herr et coll showed that of 92 patients with residual T1 cancer in WLRc-TURBT, 75 (82%) progressed to muscle invasion within 5 years compared to 49 of 260 (19%) who had no or non-T1 tumor detected on restaging cTURBT (34). A similar study reported that early cystectomy seems to prolong cancer-specific survival compared to deferred cystectomy in high-risk high-grade T1 patients (35).

Considering the high risk of progression and cancer death of high-grade T1 disease, cystectomy would be the best answer for treatment. However, there are disadvantages. First, cystectomy may be overtreatment for high-grade T1 disease. Since at least 50% of high-grade T1 patients are not upstaged upon cystectomy (36). Second, cystectomy deteriorates the quality of life. Finally, cystectomy is a highly complicated surgery in the urological field, and almost 30%-50% of patients experience perioperative or long-term complications (37).

In our experience, the most important predictive prognostic factor – in patients with pT1HG tumours – is the presence of concomitant CIS. Sylvester et al. observed in pT1HG patients without CIS a probability of progression around 10% at 1 year and 29% at 5 years. In pT1HG patients with CIS, the corresponding features are 29% and 74%, respectively (3).

**CONCLUSIONS**

WLRc-TURBT is a useful tool because in a percentage of the patients this additional surgery results in an improvement of treatment strategy. True recurrence rate can be better evaluated by this approach because residual tumors may be erroneously defined as recurrence. Our data showed that it is necessary to perform a WLRc-TURBT in patients with newly diagnosed, high grade (HG), stage pT1 bladder cancer for a ‘real’ staging and a complete resection (15% persistent disease). In our experience, following WLRc-TURBT in HGNMIBC risk group patients we identified a 15% persistent disease with a 4.3% of MBC. In the patients with persistent bladder neoplasms we observed a overall recurrence and progression rate more elevated than in T0 bladder tumours group (Δ = + 17.3% and Δ = + 62.5%).

**REFERENCES**


12. Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: A ran-
domized Southwest Oncology Group Study. J Urol. 2000; 163:1124-
1129.
15. Pearson K. On the criterion that a given system of deviations from the probable in the case of a correlated system of variables is such that it can be reasonably supposed to have arisen from random sampling. The London, Edinburgh, and Dublin Philosophical Magazine and Journal of Science - Series 5 1900; 50:157-175.

Correspondence
Roberto Giuliani, MD
giulianelli76@live.com
Barbara Cristina Gentile, MD
Gabriella Mirabile, MD
Lara Albanesi, MD
Paola Tariciotti, MD
paola.tariciotti@libero.it
Giorgio Rizzo, MD
CUrA, Nuova Villa Claudia Clinic, Rome, Italy
Maurizio Bucarini, MD
Campus BioMedico, Rome, Italy
Mauro Vermiglio, MD
Villa Gioia Clinic, Sora (FR), Italy